Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Kina vs Medro

Kina
Graded #115

Higher grade

vs+6.199999999999996
Medro
Graded #255

Lower grade

The verdict

Kina takes it — 69.8/100 to 63.6/100.

Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKina +10
60
50
Dose & formulationMedro +13
64
77
Clinical oversightKina +17
88
71
Labs & monitoringKina +12
64
52
FulfillmentMedro +9
83
92
Contract termsKina +28
61
33
Kina · left barMedro · right bar

The numbers

MetricKinaMedro
WeighScore69.8/10063.6/100
GradeCC
Scorecard rank#115#255
Semaglutide$179/mo (starting dose, plus a separate fee, compounded)$199/mo (compounded)
Tirzepatide$179/mo (starting dose, compounded)$299/mo (compounded)
CoverageCoverage not publishedAll 50 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Kina

Graded #115 · C

Strengths

  • Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
  • Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
  • Verifiable LegitScript certification (seal ID 50917967)
  • GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
  • Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Built for women navigating menopause — less tailored if that is not your situation
  • A separate $50 physician consultation fee applies on top of the medication price
  • The compounding pharmacy partner is not named, and the full list of served states is not published
Medro

Graded #255 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard